Remove 2024 Remove Radiation Oncology Remove Radiology Remove Radiopharmaceuticals
article thumbnail

The rise of theranostics: Part 5 -- Advice from center administrators

AuntMinnie

Reshaping the hospital's nuclear medicine and radiopharmaceutical strategy toward theranostics involves intensive and inclusive planning, Beyder explained at SNMMI. Theranostics offers hospital radiology departments the opportunity to keep more reimbursement dollars in the department, Beyder explained.

article thumbnail

IMV: PET scan volumes continue to grow

AuntMinnie

year over year, according to the newly published IMV 2024 PET Market Summary Report. In terms of 2023 spending, the average radiopharmaceutical expenditure per fixed PET site is estimated to be $517,000. IMV's 2024 PET Market Summary Report explores market trends in U.S. Davin Korstjens.

PET Scan 116
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GE HealthCare Closes MIM Software Acquisition

Imaging Technology

milla1cf Tue, 04/02/2024 - 18:51 April 2, 2024 — Less than three months after signing an agreement to acquire MIM Software Inc. , GE HealthCare Technologies Inc. Radiation therapy – a type of treatment given alone or in combination with surgery and/or chemotherapy – is administered to nearly two-thirds of all cancer patients.i

article thumbnail

The rise of theranostics: Part 2 -- Moving into communities

AuntMinnie

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

article thumbnail

The rise of theranostics: Part 3 -- What is a theranostics center?

AuntMinnie

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.